Liquidia

Liquidia is a commercial-stage biopharmaceutical company focused on the development and commercialization of treatments for pulmonary arterial hypertension (PAH), with its lead product YUTREPIA representing a differentiated dry powder inhaled formulation of treprostinil competing directly in a market historically dominated by United Therapeutics. The company's proprietary PRINT technology platform offers a manufacturing advantage in particle engineering, though its supply chain remains relatively concentrated given its early commercial stage and dependence on contract manufacturing relationships. Liquidia's investment thesis centers on its ability to capture meaningful market share in the multi-billion dollar PAH space as it navigates ongoing patent litigation and works to establish commercial infrastructure against an entrenched incumbent.